Leidos Awarded Contract By U.S. Navy Bureau of Medicine and Surgery Company to Provide Psychological Health Support Services to the Naval Center for Combat and Operational Stress Control
RESTON, Va., May 7, 2014 /PRNewswire/ -- Leidos (NYSE: LDOS), a national security, health and engineering solutions company, was awarded a prime contract by the U.S. Navy Bureau of Medicine and Surgery (BUMED) to provide psychological health support services to the Naval Center for Combat & Operational Stress Control (NCCOSC). The single-award cost-plus fixed- fee (CPFF) contract has a one-year base period of performance, two one-year options, and a total contract value of approximately $15 million, if all options are exercised. Work will be performed primarily in San Diego, Calif.
The NCCOSC improves the psychological health of marines and sailors through comprehensive programs that educate service members, builds resilience, aids research, and promotes best practices in the treatment of combat and operational stress injuries.
Under the contract, Leidos will develop and implement the center's education and training programs; coordinate strategic communications, external relations and outreach to important communities; support Fleet Marine Forces, Navy Line and Navy Medicine clinicians via a research facilitation department; and develop, implement and sustain the center's data management capability.
"Ensuring the psychological well-being of our military personnel is important for the long-term strength of our armed forces, and crucial for our military families when they return home," said Steve Comber, President of Leidos Health. "We are pleased to support the Navy in facilitating important research, enhancing resilience and promoting best practices in the treatment of Post-Traumatic Stress Disorder and traumatic brain injuries so that our military service members get the care and support they need for a long and healthy life."
About Leidos Health
As a leader for more than 25 years in the healthcare industry, Leidos Health fuses some of the world's most advanced technologies with the brightest minds in science, research, and consulting. Today, Leidos Health is focused on developing next-generation solutions in areas such as biomedical research, public health, and health analytics to turn data into actionable information for clinicians and their patients. From leading groundbreaking medical research to fight diseases such as cancer, AIDS, and malaria, to implementing and optimizing electronic health records that enhance the research process and improve critical efficiencies – Leidos Health's passion to improve patient care and reduce costs is helping to transform healthcare. For more information, visit www.Leidos.com/health. For more information on how Leidos supports behavioral health research and outreach, visit http://www.leidos.com/health/healthservices/outreach-training.html.
Leidos is a science and technology solutions leader working to address some of the world's toughest challenges in national security, health and engineering. The Company's 22,000 employees support vital missions for our government and the commercial sector, develop innovative solutions to drive better outcomes and defend our Nation's digital and physical infrastructure from 'new world' threats. Headquartered in Reston, Va., Leidos reported annual revenues of approximately $5.77 billion for its fiscal year ended January 31, 2014 after giving effect to the spin-off of the company's technical services and information technology business. For more information, visit www.Leidos.com.
Statements in this announcement, other than historical data and information, constitute forward-looking statements that involve risks and uncertainties. A number of factors could cause our actual results, performance, achievements, or industry results to be very different from the results, performance, or achievements expressed or implied by such forward-looking statements. Some of these factors include, but are not limited to, the risk factors set forth in the company's Annual Report on Form 10-K for the period ended January 31, 2014, and other such filings that Leidos makes with the SEC from time to time. Due to such uncertainties and risks, readers are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof.